GSK Consumer Healthcare Korea was revealed to have appointed a new chief executive officer, and it was revealed to be Shin Dong Woo, a former CEO of the company’s branch in Hong Kong.
According to The Korea Times, GSK Consumer Healthcare Korea announced the assignment of CEO Shin earlier this week. It was reported that the new chief has been with the company for 28 years and has led GSK in various international businesses - from consumer health care to general consumer goods.
He also led other health care firms such as Pfizer and Sanofi. Prior to his assignment as the new chief at GSK Consumer Healthcare Korea, he has been leading the Honk Kong unit for the last two years. During his tenure, he has many achievements, including boosting the business and building the foundation for its stability.
At Sanofi Korea, he became the first president of the He also completed the company's integration with Pfizer Consumer Healthcare, where he was CEO of the Korean branch and the Asia-Pacific region between 2015 and 2020.
Shin also became the very first president of the French multinational healthcare company’s Korean unit. He helped established the brand in the country and introduced major products that are now selling very well here., and this is not all. Shin has extensive experience in marketing as well as he worked at Coca-Cola, L’Oreal, and Fox Home Entertainment and was in charge of marketing and sales for more than a decade.
Meanwhile, Shin will lead GSK Consumer Healthcare Korea, which has recently changed its name to Haleon. This will be the company’s official name as it starts its consumer healthcare venture. The name means the company will also change all of its product packaging.
"With the announcement of 'Haleon' today, we are one step closer to our goal of becoming a consumer healthcare company,” Haleon’s CEO-nominee, Brian McNamara, said in a press release in February. “'Haleon' will stand as a leader in the consumer healthcare industry with the vision of delivering better daily health to mankind.”
“Haleon” is the outcome of the successful merging of Novartis in 2015 and Pfizer's consumer healthcare portfolio in 2019 over the past eight years.


Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook
Visa to Move European Headquarters to London’s Canary Wharf
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals
IMF Deputy Dan Katz Visits China as Key Economic Review Nears
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp
European Stocks Rise as Markets Await Key U.S. Inflation Data
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 



